Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies
A

MDS/MPN Overlap Through Interactive Case Based Discussion: Overview of Disease, Molecular / Genomic Basis, and Treatment Options

By Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies FEATURING Andrew Kuykendall
By Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies FEATURING Andrew Kuykendall
25 views
January 28, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Related Content

AUTOPLAY
27:37
Indy Hematology Review

Review of Myeloproliferative Neoplasms

Feat. A. Tefferi
18:04
Ruben Mesa

Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…

08:18
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…

Feat. A. Zhou
05:20
Prithviraj Bose

When to Switch From Hydroxyurea to Ruxolitinib in PV

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
21:52
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…

Feat. D. Tremblay
31:43
Indy Hematology Review

Myelofibrosis: Chronic and Blast Phase - 2023 Algorithms for Risk St…

Feat. A. Tefferi
24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi
10:02
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of MPNs - Highlights & Key Take…

Feat. R. Mesa
09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
12:18
Fred Hutchinson Cancer Center

Management of MPNs for the Community Oncologist

Feat. H. Deeg
16:25
Northwestern Medicine Oncology and Hematology

Diagnosis and Goals of Therapy in PV

Feat. B. Stein
12:07
Douglas Tremblay

Monitoring Patients With MF: When to Switch Treatment

11:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

2024 Updates in Myeloproliferative Neoplasms

Feat. E. Hexner
09:46
Scripps MD Anderson Cancer Center

Ruxolitinib in Polycythemia Vera: Learnings From the RESPONSE Trial

Feat. D. Hermel
08:44
Krisstina Gowin

Management of Aquagenic Pruritis in Polycythemia Vera

23:35
University of Colorado Division of Hematology

2024 Updates in PV/ET

Feat. B. McMahon
17:51
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

Chronic GVHD: A Case-Based Discussion

Feat. L. Perry
51:20
Jerry Spivak

Polycythemia Vera: Disease Overview, Treatment Landscape, and Curren…

15:31
Icahn School of Medicine at Mount Sinai

Myelofibrosis Treatment Options Beyond the JAK/STAT Pathway

Feat. M. Kremyanskaya